Analytik reports how its Microfluidizer® processors are enabling researchers develop a range of therapeutic formulations including vaccine adjuvants, liposomes and lipid nanoparticles. By reducing particle size uniformly, Microfluidizers from Analytik are helping a growing number of pharmaceutical companies and Contact Development and Manufacturing Organisations (CDMOs) improve the efficacy, bioavailability, stability and process efficiency of their
A team of scientists from Spain has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine developed by Pfizer-BioNTech (BNT162b2). Their findings reveal that a 2-dose regimen of BNT162b2 vaccine is capable of providing almost 100% protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in healthcare workers. The study is
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and
While rare, botulism can cause paralysis and is potentially fatal. It is caused by nerve-damaging toxins produced by Clostridium botulinum—the most potent toxins known. These toxins are often found in contaminated food (home canning being a major culprit). Infants can also develop botulism from ingesting C. botulinum spores in honey, soil, or dust; the bacterium
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites
A Purdue University-patented technology shows promise in using microscopic bubbles filled with oxygen to help with various medical treatments, including improving cancer therapeutics and helping wounds heal faster. Samara Biotech LLC, a Purdue startup, has developed an easy-to-use method to inject oxygen “nanobubbles” intravenously so they can be targeted precisely at wounds or cancerous tumors.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok